Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Ho

Showing results (71-80 of 192) with videos related to

Pageof 20
Sort By:
CNS Spectrums|June 2, 2025
A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomniaKyle Valentino, Kayla Teopiz, Sabrina Wong, et al.
Frontiers in Psychiatry|February 26, 2021
Impact of the COVID-19 Pandemic on Physical and Mental Health in Lower and Upper Middle-Income Asian Countries: A Comparison Between the Philippines and ChinaMichael Tee, Cuiyan Wang, Cherica Tee, et al.
Journal of Psychiatric Research|October 7, 2021
Onset and frequency of depression in post-COVID-19 syndrome: A systematic reviewOlivier Renaud-Charest, Leanna M W Lui, Sherry Eskander, et al.
Journal of Affective Disorders|July 19, 2024
A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse existsAngela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, et al.
Expert Opinion on Drug Safety|May 28, 2024
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)Roger S McIntyre, Sabrina Wong, Angela T H Kwan, et al.
Journal of Affective Disorders|April 18, 2024
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysisCameron N Calder, Angela T H Kwan, Kayla M Teopiz, et al.
Bipolar Disorders|November 26, 2021
Deficits of social cognition in bipolar disorder: Systematic review and meta-analysisEmily S Gillissie, Leanna M W Lui, Felicia Ceban, et al.
Journal of Affective Disorders|October 21, 2024
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)Roger S McIntyre, Rodrigo B Mansur, Joshua D Rosenblat, et al.
Journal of the Royal Society of Medicine|September 22, 2021
Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reductionRoger S McIntyre, Leanna Mw Lui, Joshua D Rosenblat, et al.
Journal of Psychiatric Research|September 19, 2020
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Pageof 20

Showing results (71-80 of 192) with videos related to

Sort By:
Pageof 20
CNS Spectrums|June 2, 2025
A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomniaKyle Valentino, Kayla Teopiz, Sabrina Wong, et al.
Frontiers in Psychiatry|February 26, 2021
Impact of the COVID-19 Pandemic on Physical and Mental Health in Lower and Upper Middle-Income Asian Countries: A Comparison Between the Philippines and ChinaMichael Tee, Cuiyan Wang, Cherica Tee, et al.
Journal of Psychiatric Research|October 7, 2021
Onset and frequency of depression in post-COVID-19 syndrome: A systematic reviewOlivier Renaud-Charest, Leanna M W Lui, Sherry Eskander, et al.
Journal of Affective Disorders|July 19, 2024
A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse existsAngela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, et al.
Expert Opinion on Drug Safety|May 28, 2024
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)Roger S McIntyre, Sabrina Wong, Angela T H Kwan, et al.
Journal of Affective Disorders|April 18, 2024
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysisCameron N Calder, Angela T H Kwan, Kayla M Teopiz, et al.
Bipolar Disorders|November 26, 2021
Deficits of social cognition in bipolar disorder: Systematic review and meta-analysisEmily S Gillissie, Leanna M W Lui, Felicia Ceban, et al.
Journal of Affective Disorders|October 21, 2024
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)Roger S McIntyre, Rodrigo B Mansur, Joshua D Rosenblat, et al.
Journal of the Royal Society of Medicine|September 22, 2021
Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reductionRoger S McIntyre, Leanna Mw Lui, Joshua D Rosenblat, et al.
Journal of Psychiatric Research|September 19, 2020
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Pageof 20